1. Home
  2. Medicines: our clinical trials
  3. Clinical Studies
  4. CDT : Clinical Studies (current)
scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.

 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date Planned End date

A Prospective Non-Interventional Study on STRUctum® in Adult Patients with oSTeoarthritis – TRUST

 		Rhumatology Real world study Completed July 2023 October 2024

The performance and safety of Petit Drill in the French paediatric population: a post-marketed clinical follow-up.

 		Otorhinolaryngology Real world study Early termination March 2024 November 2024

Multicenter, Open-label, Phase II Study with a Safety Lead-in part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAFV600E mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer who are BRAF- and MEK inhibitor treatment-naïve

 		Oncology Phase II Active not recruiting May 2024 April 2026

Study of FIH of STX-241 in locally advanced or metastatic NSCLC resistant to EGFR TKIs (STX-241FIH)

 		Oncology Phase I / II Active September 2024 July 2030

Impact of dermatological toxicities on quality of life in patients with early breast cancer exposed to adjuvant endocrine therapy: a real-world cross-sectional study - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological adverse events)

 		Oncology Real world study Active not recruiting November 2024

An observational, Post-Authorisation Safety Study (PASS) to describe the safety and effectiveness of tabelecleucel in patients with Epstein-Barr Virus positive (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) in a real-world setting in Europe : Ebvolve study

 		Oncology Real world study Recruiting January 01, 2025
21 - 26 over 26

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

Phase III  -  COLUMBUS

SPONSOR: PFIZER

Breast cancer 

Phase III    -    EXTENET

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

Phase III - BEACON CRC

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

Phase III     -       ALLELE

SPONSOR: ATARA